Highlights

The most relevant and impactful activities of the SWG include those related to the guideline development project.

There were regular meetings with the Guidelines Expert Panel Committee.

SWG business meetings were held to discuss the progress in the development of the guidelines for the use and reporting of patient-reported outcomes in adult clinical trials.

Regular meetings were held with Cochrane Haematology and the University of Cologne specialists involved in the systematic review process.

Systematic reviews for these guidelines are in progress.

Advancements

Supportive Care in hematological cancer session at EHA2025

Chair – Esther Oliva (United Kingdom)

Presenters and topics

  • ‘Anemia management (QoL and transfusion in MDS)’ – Marlijn Hoeks (Netherlands)
  • ‘SWG supportive care overview’—Justin Loke (United States)

SWG-organized session at EHA2025

Presenters and topics

  • ‘Assessment of patients’ quality of life and symptoms in routine clinical practice to aid treatment decision making’—Raul Cordoba (Spain)
  • ‘Quality of life in cardio-hematology : Lessons from the Horizon 2020 Resilience Trial’— Borja Ibanez (Spain)
  • ‘Treatment outcomes preferences: What matters to patients with acute leukemia?’— Jan Geissler (Germany)

2026 priorities

The SWG’s top three follow-up activities for the next year are the:

  • Finalization of the guidelines for PRO assessment in lymphoproliferative neoplasms, myeloproliferative neoplasms, leukemias and myelodysplastic neoplasms
  • Preparation of the SWG’s session at EHA2026 and EHA2027
  • Publication of the systematic review articles in leukemias, and MDS
Share